menu
    • menu
    [{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Sonoma Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"Treg therapy","moa":"T cell","graph1":"Immunology","graph2":"Undisclosed","graph3":"Lyell Immunopharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Lyell Immunopharma \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Lyell Immunopharma \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Eureka Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series E Financing","leadProduct":"ET140202","moa":"Alpha-fetoprotein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lyell Immunopharma","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Lyell Immunopharma \/ Lyell Immunopharma","highestDevelopmentStatusID":"7","companyTruncated":"Lyell Immunopharma \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"CAR T-Cell therapy","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lyell Immunopharma \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Lyell Immunopharma \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Orca Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"T cell therapies","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lyell Immunopharma \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Lyell Immunopharma \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"LYL797","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lyell Immunopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Not Applicable"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"NY-ESO-1","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lyell Immunopharma \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ GSK"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"LYL797","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lyell Immunopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Not Applicable"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"LYL845","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lyell Immunopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Not Applicable"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"LYL845","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lyell Immunopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Not Applicable"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"LYL845","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lyell Immunopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Not Applicable"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"LYL797","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lyell Immunopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Not Applicable"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"ImmPACT Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Acquisition","leadProduct":"IMPT-314","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lyell Immunopharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lyell Immunopharma \/ Lyell Immunopharma","highestDevelopmentStatusID":"12","companyTruncated":"Lyell Immunopharma \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"ImmPACT Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Acquisition","leadProduct":"IMPT-314","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lyell Immunopharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lyell Immunopharma \/ Lyell Immunopharma","highestDevelopmentStatusID":"12","companyTruncated":"Lyell Immunopharma \/ Lyell Immunopharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Lyell Immunopharma

    Menu

    Lyell Immunopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lyell Immunopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Lyell Immunopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMPT-314

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : ImmPACT Bio

                            Deal Size : $30.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lyell Immunopharma Completes Acquisition of ImmPACT Bio

                            Details : Lyell will acquire worldwide rights to ImmPACT’s pipeline, the next- gen CD19/CD20 autologous CAR T-cell therapy, which includes IMPT-314, it is currently in clinical development for B-cell lymphoma.

                            Brand Name : IMPT-314

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $30.0 million

                            October 31, 2024

                            Lead Product(s) : IMPT-314

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : ImmPACT Bio

                            Deal Size : $30.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lyell Immunopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Lyell Immunopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMPT-314

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : ImmPACT Bio

                            Deal Size : $30.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lyell Immunopharma Acquires ImmPACT Bio, Refocuses on CAR T-cell Therapy

                            Details : Lyell will acquire worldwide rights to ImmPACT’s pipeline, the next- gen CD19/CD20 autologous CAR T-cell therapy, which includes IMPT-314, it is currently in clinical development for B-cell lymphoma.

                            Brand Name : IMPT-314

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $30.0 million

                            October 24, 2024

                            Lead Product(s) : IMPT-314

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : ImmPACT Bio

                            Deal Size : $30.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lyell Immunopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Lyell Immunopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LYL797

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lyell Reports Dose-dependent Activity from Phase 1 of LYL797, ROR1-targeted CAR-T

                            Details : LYL797 is a receptor tyrosine kinase-like orphan receptor 1 (ROR1) targeted CAR T‑cell product, being developed for ROR1+ triple negative breast cancer or non-small cell lung cancer.

                            Brand Name : LYL797

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 26, 2024

                            Lead Product(s) : LYL797

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lyell Immunopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Lyell Immunopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LYL845

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

                            Details : LYL845 is an investigational autologous TIL product enhanced with Epi-R manufacturing protocols for patients with relapsed and/or refractory metastatic or locally advanced melanoma, NSCLC and CRC.

                            Brand Name : LYL845

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 09, 2023

                            Lead Product(s) : LYL845

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Lyell Immunopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Lyell Immunopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LYL845

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its No...

                            Details : LYL845 is an investigational tumor infiltrating lymphocyte (TIL) therapy enhanced with Lyell’s Epi-R™ technology for patients with relapsed and/or refractory metastatic or locally advanced melanoma and other select solid tumors.

                            Brand Name : LYL845

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 06, 2022

                            Lead Product(s) : LYL845

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Lyell Immunopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Lyell Immunopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LYL845

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Grow...

                            Details : LYL845 is Lyell’s autologous tumor infiltrating lymphocyte (TIL) product candidate enhanced via Epi-R™, a proprietary epigenetic reprogramming technology, designed to create products with higher proportions of stem-like T cells.

                            Brand Name : LYL845

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 05, 2022

                            Lead Product(s) : LYL845

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Lyell Immunopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Lyell Immunopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LYL797

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022

                            Details : LYL797 is an investigational chimeric antigen receptor (CAR) T-cell therapy for patients with receptor tyrosine kinase-like orphan receptor 1-positive (ROR1+) solid tumors.

                            Brand Name : LYL797

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 12, 2022

                            Lead Product(s) : LYL797

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Lyell Immunopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Lyell Immunopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LYL132,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : GSK

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lyell Immunopharma to Present Preclinical Data for Two Product Candidates in Clinical Development at ASGCT Ann...

                            Details : GSK4427296 (LYL132) an investigational T-cell receptor, incorporates Epi-R reprogramming technology and is under investigation as a potential next-generation enhancement to letetresgene autoleucel for patients with solid tumors.

                            Brand Name : GSK4427296

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 02, 2022

                            Lead Product(s) : LYL132,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : GSK

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Lyell Immunopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Lyell Immunopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LYL797

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (...

                            Details : LYL797 is an investigational chimeric antigen receptor (CAR) T-cell therapy for patients with receptor tyrosine kinase-like orphan receptor 1-positive (ROR1+) solid tumors. The presentation will highlight the preclinical data characterizing LYL797.

                            Brand Name : LYL797

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 08, 2022

                            Lead Product(s) : LYL797

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Lyell Immunopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Lyell Immunopharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T cell therapies

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Orca Bio

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Orca Bio and Lyell Immunopharma Announce Research Partnership

                            Details : The partnership promotes complementary scientific technologies to develop next generation cell-based therapies for patients with solid cancers.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 02, 2020

                            Lead Product(s) : T cell therapies

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Orca Bio

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth